Autologous stem cell therapy - Lifecells LLC

Drug Profile

Autologous stem cell therapy - Lifecells LLC

Alternative Names: ASCT01

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lifecells LLC
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral ischaemia

Most Recent Events

  • 01 Mar 2016 Lifecells completes a phase I/II trial in Peripheral ischaemia in USA (Intra-arterial, IM) (NCT01867190)
  • 11 Dec 2015 Phase I/II development is ongoing in USA (IM & Intra-arterial)
  • 31 May 2013 Phase-I/II clinical trials in Peripheral ischaemia in USA (IM) (NCT01867190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top